Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of the Safety and Efficacy of Tag-7 Gene-modified Tumor Cell-based Vaccine in Patients With Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer

NCT04180774 is registered in ClinicalTrials.gov with N.N. Petrov National Medical Research Center of Oncology as lead sponsor.

NCT NCT04180774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04180774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of the Safety and Efficacy of Tag-7 Gene-modified Tumor Cell-based Vaccine in Patients With Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer
Lead sponsor
N.N. Petrov National Medical Research Center of Oncology
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2001
Completion date
December 31, 2018
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, melanoma